Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
This study will employ a single-center, randomized, double-blind parallel-group design for
MNTX and placebo, with a positive control (moxifloxacin) dosed single-blind to confirm
methodology, in normal healthy male and female volunteers. Multiple ECGs will be obtained
after single clinical and supratherapeutic doses of MNTX to assess ECG effects compared to
placebo.
Phase:
Phase 1
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.